Citi Starts Larimar Therapeutics (LRMR) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts LRMR Hot Sheet
Price: $2.35 +3.52%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Citi analyst Samantha Semenkow initiates coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Neutral rating and a price target of $4.00.
For an analyst ratings summary and ratings history on Larimar Therapeutics click here. For more ratings news on Larimar Therapeutics click here.
Shares of Larimar Therapeutics closed at $3.89 yesterday.
You May Also Be Interested In
- Citi Starts Yamazaki Baking Co Ltd (2212:JP) at Buy
- Canaccord Starts Kimberly Clark (KMB) at Hold
- Needham Starts Diodes (DIOD) at Buy, 'Significant Margin Upside'
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
